Márk Barok
Impact in
- Oncology top 2%
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- Cancer Cells and Metastasis
-
- Monoclonal and Polyclonal Antibodies Research
Papers in
- Oncology 18
- HER2/EGFR in Cancer Research 16
- Peptidase Inhibition and Analysis 2
- Cancer Cells and Metastasis 2
-
- Monoclonal and Polyclonal Antibodies Research 12
- Co-authors
- Jorma Isola (14 shared papers)Heikki Joensuu (11 shared papers)Minna Tanner (5 shared papers)János Szöllõsi (7 shared papers)György Vereb (7 shared papers)Péter Nagy (4 shared papers)Maija Puhka (3 shared papers)Pirjo Laakkonen (6 shared papers)
In The Last Decade
Márk Barok
22 papers receiving 1.7k citations
Márk Barok's Hit Papers
Peers
Comparison fields: 5 of 73
- Oncology 1.2k
- Radiology, Nuclear Medicine and Imaging 725
- Immunology and Allergy 117
- Cancer Research 169
- Genetics 96
Countries citing papers authored by Márk Barok
This map shows the geographic impact of Márk Barok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Márk Barok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Márk Barok more than expected).
Fields of papers citing papers by Márk Barok
This network shows the impact of papers produced by Márk Barok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Márk Barok. The network helps show where Márk Barok may publish in the future.
Co-authors
The 25 scholars most cited alongside Márk Barok, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Trastuzumab emtansine: mechanisms of action and drug resistance Hit paper breakdown → | 2014 | 446 |
| 2 | 2007 | 183 | |
| 3 | 2011 | 183 | |
| 4 | 2011 | 128 | |
| 5 | 2007 | 123 | |
| 6 | 2010 | 90 | |
| 7 | 2019 | 74 | |
| 8 | 2018 | 74 | |
| 9 | 2007 | 73 | |
| 10 | 2008 | 72 | |
| 11 | 2020 | 69 | |
| 12 | 2008 | 57 | |
| 13 | 2007 | 40 | |
| 14 | 2021 | 32 | |
| 15 | 2008 | 30 | |
| 16 | 2024 | 13 | |
| 17 | 2023 | 8 | |
| 18 | 2025 | 5 | |
| 19 | 2025 | 4 | |
| 20 | 2016 | 4 |
About Márk Barok
Márk Barok is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Molecular Biology, Immunology and Allergy and Cell Biology, having authored 23 papers that have together received 1.7k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (16 papers), Monoclonal and Polyclonal Antibodies Research (12 papers), Cell Adhesion Molecules Research (4 papers), Cancer Genomics and Diagnostics (2 papers), Glycosylation and Glycoproteins Research (2 papers), Peptidase Inhibition and Analysis (2 papers), Proteoglycans and glycosaminoglycans research (2 papers) and Cancer Cells and Metastasis (2 papers). The work is most often cited by research in Oncology (1.2k citations), Radiology, Nuclear Medicine and Imaging (725 citations), Immunology and Allergy (117 citations), Cancer Research (169 citations) and Genetics (96 citations). Márk Barok has collaborated with scholars based in Finland, Hungary and Canada. Frequent co-authors include Jorma Isola, Heikki Joensuu, Minna Tanner, János Szöllõsi, György Vereb, Péter Nagy, Maija Puhka, Pirjo Laakkonen, István Juhász and Vadim Le Joncour. Their work appears in journals such as Cancer Letters, Molecular Cancer Therapeutics, Breast Cancer Research, Journal of Extracellular Vesicles and Cytometry Part A.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.